Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

See How We Drive Progress Further, Faster

The Latest Issue of The Evidence Forum – Summer 2022

Evidera’s publication is a compilation of white papers addressing key issues. This issue focuses on Looking Forward, with topics such as CAR-T cell therapy, drug safety, pediatric drug development, and others.

Read Now

PPD OncoLocator

Real-time understanding of treatment patterns in common cancers

Learn More

Career Opportunities

Join Our Growing Team

We’re looking for smart, creative, dedicated, people to join us in optimizing patient access with evidence of value, effectiveness, and safety

Learn More

Blog Post

Six Trends Influencing the Future of Real-World Evidence

The evidence is in: From market access to patient centricity, drug developers that conquer these key areas will be best poised for product delivery and commercial success. Here’s how to do so.

Read Now

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Cardiovascular

Net Clinical Benefit of Antiplatelet Therapy was Affected by Patient Preferences: A Personalized Benefit-Risk Assessment

February 2022

Endocrinology

Cost-Effectiveness of Second-Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States

Diabetes Obesity & Metabolism
February 2022

Nephrology

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG Outcome Trial

American Journal of Kidney Diseases
February 2022

What We Do

Real-World Evidence & Data Solutions

Obtain real-world evidence to optimize product value, effectiveness, safety, and market strategy by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Non-Interventional Studies

Robust design, epidemiologic and therapeutic area insights, advanced data analytics and precision study execution critical for study and program success.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Value & Development Consulting

End-to-end regulatory, clinical development, and value and access consulting services that span all phases of development.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.

In Our Own Words

We are optimizing protocol development and operations in oncology trials, including better anticipation of post-approval needs that can be integrated earlier into trial designs, providing crucial data for activities focused on market access.

Dirk Reitsma, MD, Vice President, Head of Oncology Global Product Development, PPD

Oncology – An Exciting Time of New Hope and New Challenges Feature Image

Case Study

Embedded Qualitative Patient Interviews Support Regulatory Approval of Novel Oncology Treatment

Discover how Evidera’s Patient-Centered Research team helped to conduct embedded qualitative interviews that provided insights to lessen regulatory concerns about treatment side effects.

Case Study

Real-World Data Insights from LiveTracker® Determine Prescribing Trends for Cancers with High PD-L1 Protein Expression

Evidera's Real-World Data Solutions team used LiveTracker to evaluate HCP-reported data on treatment patterns in patients with non-small cell lung cancer and melanoma.

Case Study

Oncology Developer Utilizes Integrated Scientific Advice to Optimize Phase III Trial, Aligning Regulator and HTA Needs

Gain insight into how Evidera’s Value & Development Consulting team leveraged our Integrated Scientific Advice (ISA) offering to provide feedback to drug developers to optimize their evidence generation plans and satisfy stakeholder requirements.

Case Study

Six-Year Collaboration Across Six Indications for Groundbreaking Oncology Therapy

Evidera's Evidence Synthesis, Modeling & Communication team generated integrated packages of evidence, including value messaging, systematic reviews and comparative effectiveness analyses, and economic models, for six indications.

Case Study

Virtual Expanded Access Program Providing Breast Cancer Patients Early Access to Treatment During the COVID-19 Pandemic

Evidera was able to provide a virtual approach to mitigate the risk to patient safety during the COVID-19 pandemic and enabled early patient access to 400 US breast cancer patients ahead of commercial availability.

Case Study

Enhancing Oncology Market Access with a Real-World Evidence EAMS Add-on

Discover how Evidera researchers designed an observational study to conceptualize and implement real-world data collection in an Early Access to Medicines Scheme (EAMS) for an oncology therapy.

Case Study

Evidera Led Effort to Qualify the First Biomarker for COPD Trial Enrichment

Learn how Evidera's partnership with the COPD Foundation Biomarker Qualification Consortium led to the qualification of plasma fibrinogen as the first biomarker in COPD for enrichment of clinical trials by the FDA.

Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More